Q3 FY2026 EarningsQ3 FY26 significantly missed revenue consensus at $8,700 vs. $0.97M expected, primarily due to higher-than-forecasted returns in European markets. Net loss of $20.3M was wider than the $11.2M consensus, impacted by a $7.0M non-cash loss on warrant liability adjustments. Despite the financial miss, the July 2024 FDA approval of LYTENAVA for the treatment of Wet AMD serves as a critical catalyst for the upcoming U.S. commercial launch in Q4 FY26.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Outlook Therapeutics(OTLK) the Revenue is 9 K (-99.4%), Miss estimate;the EBIT is -10.81 M (+31.36%), Miss estimate;the EPS is -0.15 (+72.73%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B99.40%
0.00B35.77%
-0.00B63.63%
EBITMiss expectations
-0.01B31.36%
-0.01B31.45%
-0.00B0.09%
EPSMiss expectations
-0.1572.73%
-0.0885.45%
-0.070012.72%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf